Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Evaluating the effects of hypoglossal nerve stimulation on metabolism in sleep apnea patients

Official title: Cardiometabolic Risk Effects of Short-term Cessation of Effective Neurostimulation Therapy in OSA

Run by Columbia University · NCT06720545 · Data updated 2026-11-12

This study is testing if a therapy that stimulates a nerve in the tongue can help people with sleep apnea improve their metabolism and reduce health risks.

More Obstructive Sleep Apnea trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment60 (estimated)
SponsorColumbia University
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedJanuary 5, 2025
Main results expectedJanuary 2027
Study endsJanuary 2028
Registry record updatedJuly 10, 2025
Trial IDNCT06720545 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are English-speaking adults aged 18 and older who have been using HGNS therapy effectively for at least three months.

Probably not a fit

Patients with chronic opiate use, pregnancy, or severe excessive daytime sleepiness may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of hypoglossal nerve stimulation (HGNS) therapy on metabolic outcomes and inflammation in patients with obstructive sleep apnea (OSA). Participants will have been using HGNS for at least three months and will undergo assessments to determine if the therapy reduces their risk of medical complications associated with OSA. The study aims to provide insights into how HGNS may influence metabolic health in this patient population.

Why it matters

Potential benefit: If successful, this study could lead to improved metabolic health and reduced medical risks for patients with obstructive sleep apnea.

How similar studies have gone: While hypoglossal nerve stimulation has been studied, this specific focus on metabolic outcomes is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* English-speaking adults (18+ years) who have met surgical efficacy criteria with HGNS, as defined by at least a 50% reduction in apnea-hypopnea index (AHI) to \<20 (with hypopneas defined by 4% oxyhemoglobin desaturations)
* Have been using HGNS therapy for at least 3 months and used HGNS for \>20 hours/week during the past 4 weeks
* Were not using any OSA therapy for at least one month prior to HGNS activation or have had a one-month period of untreated OSA after HGNS activation

Exclusion Criteria:

* Chronic use of opiate medications, illicit drugs, or alcohol dependency
* Women who are pregnant or planning to become pregnant
* Shift workers, heavy machinery operators, or commercial drivers
* History of severe excessive daytime sleepiness (Epworth Sleepiness Scale score \>16 at time of screening or prior to HGNS), motor vehicle accidents or near-miss incidents due to drowsy driving within the year prior to enrollment
* Significant cardiopulmonary (such as home oxygen requirement), liver, renal, or oncologic disease; neurodegenerative disease; active or recent history of an eating disorder (within the last 5 years)
* Inability to provide informed consent

Where it's running

  • Columbia University Medical Center
    New York, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.